株洲千金药业股份有限公司2025 年半年度报告 公司代码：600479 公司简称：千金药业 株洲千金药业股份有限公司 2025 年半年度报告 1 / 172 株洲千金药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人蹇顺、主管会计工作负责人彭意花及会计机构负责人（会计主管人员）王周杨 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投 资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-045 株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易报告书（草案） （注册稿）修订说明的公告 公司结合本次交易实际情况，对前次申请文件内容进行了更新和修订，相较 公司于 2025 年 8 月 8 日披露的《株洲千金药业股份有限公司发行股份及支付现 金购买资产暨关联交易报告书（草案）（上会稿）》，本次披露的重组报告书对部 分内容进行了更新和修订，主要情况如下： | 报告书（草案）章节 | 修订情况 | | --- | --- | | 目录 | 根据修订情况更新目录 | | 重大事项提示 | 1、更新了本次交易已履行的决策和审批程序 | 1 | 报告书（草案）章节 | | 修订情况 | | --- | --- | --- | | | | 2、补充了标的公司财务报告截止日后经营情况 | | 第一节 | 本次交易概况 | 更新了本次交易已履行的决策和审批程序 | | 第四节 | 标的公司基本 | 补充、更新了标的公司主要经营资质情况 | | 情况 | | | | 第七节 | 本次交易合同 | 补充了《业绩补偿协议之补充协议（二）》的 ...

千金药业 发行股份及支付现金购买资产暨关联交易报告书（草案） 证券代码：600479 证券简称：千金药业 上市地点：上海证券交易所 株洲千金药业股份有限公司 发行股份及支付现金购买资产 暨关联交易报告书（草案）（注册稿） | 项目 | 交易对方 | | --- | --- | | 发行股份及 | 株洲市国有资产投资控股集团有限公司、淮安市列邦康泰化工有限公司、黄 | | | 阳、汤振军、汤曜铭、唐闻伯、邓汝腾、叶胜利、刘金玉、周莉华、金亮、 | | 支付现金购 | | | | 钟林波、张新民、彭华军、王洪锋、雷颖、丁四海、刘军明、陈积安、罗斌、 | | 买资产 | | | | 殷文新、吴永强、彭彩霞 | 独立财务顾问 签署日期：二〇二五年八月 千金药业 发行股份及支付现金购买资产暨关联交易报告书（草案） 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书及其摘要内容的真实、 准确、完整，对报告书的虚假记载、误导性陈述或重大遗漏负相应的法律责任。 本公司控股股东、董事、监事、高级管理人员声明：如本次交易所披露或提 供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 中国证监会立案 ...

千金药业 发行股份及支付现金购买资产暨关联交易报告书（草案）摘要 证券代码：600479 证券简称：千金药业 上市地点：上海证券交易所 株洲千金药业股份有限公司 发行股份及支付现金购买资产 暨关联交易报告书（草案）摘要 （注册稿） | 项目 | 交易对方 | | --- | --- | | 发行股份及 | 株洲市国有资产投资控股集团有限公司、淮安市列邦康泰化工有限公司、黄 | | | 阳、汤振军、汤曜铭、唐闻伯、邓汝腾、叶胜利、刘金玉、周莉华、金亮、 | | 支付现金购 | | | | 钟林波、张新民、彭华军、王洪锋、雷颖、丁四海、刘军明、陈积安、罗斌、 | | 买资产 | | | | 殷文新、吴永强、彭彩霞 | 独立财务顾问 签署日期：二〇二五年八月 千金药业 发行股份及支付现金购买资产暨关联交易报告书（草案）摘要 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书及其摘要内容的真实、 准确、完整，对报告书的虚假记载、误导性陈述或重大遗漏负相应的法律责任。 本公司控股股东、董事、监事、高级管理人员声明：如本次交易所披露或提 供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-044 株洲千金药业股份有限公司 2025 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 报告期内，中药材及饮片生产板块营业收入较上年同期下降 47.91%，营业成本较上年同期下降 46.20%，主要是由于药材市场竞 争及波动影响所致； | | | | | 营业 | 营业 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 收入 | 成本 | 毛利率 | | | | | 毛利 | 比上 | 比上 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率（%） | 年同 | 年同 | 同期增 | | | | | | 期增 | 期增 | 减（%） | | | | | | 减（%） | 减（%） | | | 药品生 产 | 1,002,314,561.98 | 320,812,474.13 | 67.99 | 7.20 | 7.21 | 持平 | | 中药材 | | | | ...

证券代码：600479 证券简称：千金药业 公告编号：2025-043 株洲千金药业股份有限公司 株洲千金药业股份有限公司（以下简称"公司"）拟通过发行股份及支付现 金方式购买湖南千金湘江药业股份有限公司 28.92%的股权及湖南千金协力药业 有限公司 68.00%的股权（以下简称"本次交易"）。 上海证券交易所并购重组审核委员会（以下简称"上交所重组委"）于 2025 年 8 月 18 日召开 2025 年第 12 次并购重组审核委员会审议会议，对公司本次交 易的申请进行了审议。根据上交所重组委发布的《上海证券交易所并购重组审核 委员会 2025 年第 12 次审议会议结果公告》，本次会议的审议结果为：本次交易 符合重组条件和信息披露要求。 本次交易尚需经中国证券监督管理委员会同意注册后方可实施。本次交易能 否取得注册，以及取得注册的时间均存在不确定性，公司将根据审核进展情况及 时履行信息披露义务，敬请广大投资者关注后续公告并注意相关投资风险。 特此公告。 株洲千金药业股份有限公司 2025 年 8 月 20 日 1 关于发行股份及支付现金购买资产暨关联交易事项获得上 海证券交易所并购重组审核委员会审核通过 ...

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the restructuring committee for its share issuance to acquire assets, which is expected to enhance its control over subsidiaries and strengthen management [1][5]. Group 1: Transaction Details - The transaction involves issuing shares to acquire a total of 28.92% equity in Qianjin Xiangjiang Pharmaceutical and 68.00% equity in Qianjin Xieli Pharmaceutical [2][3]. - The total transaction price for the acquired assets is 62,346.69 million yuan, with 362.54 million yuan paid in cash and 61,984.15 million yuan through share issuance [4][5]. - The share issuance price is set at 8.77 yuan per share, which is 80% of the average trading price over the previous 120 trading days [2][5]. Group 2: Valuation and Financial Impact - The valuation reports indicate that the equity of Qianjin Xiangjiang Pharmaceutical is assessed at 124,670.00 million yuan, reflecting an increase of 87.77% from its book value, while Qianjin Xieli Pharmaceutical is valued at 38,671.00 million yuan, showing a 73.28% increase [3][4]. - After the transaction, Qianjin Pharmaceutical's total share capital will increase to 494,674,584 shares, with the controlling shareholder, Zhuzhou Guotou, increasing its direct holding to 34.11% [5][6]. Group 3: Strategic Implications - The acquisition will enhance Qianjin Pharmaceutical's control over its subsidiaries, increasing its stake in Qianjin Xiangjiang Pharmaceutical to 79.92% and 100% in Qianjin Xieli Pharmaceutical [5]. - This move is expected to facilitate better management and coordination within the company, aligning with its strategic plan of "one main and two auxiliary" [5].

北京商报讯（记者 丁宁）8月18日晚间，上交所官网显示，上交所并购重组审核委员会2025年第12次审 议会议于8月18日召开，审议千金药业（600479）发行股份购买资产事项，审议结果为本次交易符合重 组条件和信息披露要求。 在重组委会议上，重组委要求公司代表结合本轮以及后续可能的药品集采影响、历史毛利率变化等，说 明标的公司预测期内主要产品毛利率水平的确定依据及合理性。此外，要求公司代表结合未来战略发展 规划、药品注册批件情况、产能利用率等，说明本次交易在产品资源整合、提升药品注册批件价值上的 具体表现，以及对标的公司整合管控安排的信息披露是否充分。 据悉，千金药业拟分别收购湖南千金湘江药业股份有限公司28.92%的股权及湖南千金协力药业有限公 司68%的股权。 ...

Core Viewpoint - Qianjin Pharmaceutical (600479) is set to undergo a significant asset acquisition review on August 18, aiming to enhance its Western medicine segment through the purchase of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, despite facing challenges such as declining profits and sales prices in its target companies [1][3][5]. Group 1: Acquisition Details - Qianjin Pharmaceutical plans to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623 million yuan [3][8]. - Post-acquisition, Qianjin Pharmaceutical's stake in Qianjin Xiangjiang will increase to 79.92%, achieving 100% control over Qianjin Xieli [3][4]. - The acquisition aims to address the mismatch between capital investment and returns from the target companies, thereby improving profitability [3][6]. Group 2: Financial Performance of Target Companies - Qianjin Xiangjiang Pharmaceutical reported revenues of 640 million yuan and 704 million yuan for 2023 and 2024, with net profits of 105 million yuan and 106 million yuan respectively [6]. - Qianjin Xieli Pharmaceutical's revenues for the same period were 232 million yuan and 248 million yuan, with net profits declining from 39.16 million yuan to 23.84 million yuan [6]. - The decline in Qianjin Xieli's net profit is attributed to increased R&D investments in new heart and liver drugs [6][7]. Group 3: Market Challenges - Qianjin Xiangjiang's key product, Valsartan capsules, experienced price drops of 14.65% and 18.52% in 2023 and 2024, respectively, alongside declines in other major products [7][8]. - The pharmaceutical market is facing overall price reductions due to various factors, including national drug price negotiations and the expiration of patents [7][8]. - Experts suggest that the acquisition committee will focus on the ongoing profitability of the target assets during the review [7][8]. Group 4: Valuation and Payment Structure - The acquisition involves a mix of cash and stock payments, with the share issuance price set at 8.41 yuan per share, representing a discount compared to the market price of 10.9 yuan [8][9]. - The valuation of Qianjin Xiangjiang and Qianjin Xieli shows significant premiums, with respective increases of 87.77% and 73.28% over their book values [10].

Core Viewpoint - Qianjin Pharmaceutical is set to undergo a significant asset acquisition review on August 18, aiming to enhance its western medicine segment through the purchase of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, despite facing challenges such as declining profits and sales prices in its target companies [1][3][6]. Group 1: Acquisition Details - Qianjin Pharmaceutical plans to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623 million yuan [3][8]. - Post-acquisition, Qianjin Pharmaceutical's stake in Qianjin Xiangjiang will increase to 79.92%, and it will gain 100% control over Qianjin Xieli [3][4]. - The acquisition aims to address the mismatch between capital investment and returns in the target companies, thereby improving profitability [3][4]. Group 2: Financial Performance of Target Companies - Qianjin Xieli Pharmaceutical is projected to see a decline in net profit in 2024, while Qianjin Xiangjiang has experienced a drop in sales prices for its main products [1][6]. - Financial data indicates that Qianjin Xiangjiang's revenue for 2023 and 2024 was 640 million yuan and 704 million yuan, with net profits of 105 million yuan and 106 million yuan, respectively [6]. - Qianjin Xieli's revenue for the same period was 232 million yuan and 248 million yuan, with net profits of approximately 39 million yuan and 24 million yuan [6]. Group 3: Market Challenges - Both target companies face risks from declining drug prices and sales volumes, influenced by national pricing policies and market dynamics [7][6]. - Qianjin Xiangjiang's key product, Valsartan capsules, saw price drops of 14.65% and 18.52% in 2023 and 2024, respectively [7]. - The overall drug market is experiencing price declines due to various factors, including patent expirations and increased competition [7]. Group 4: Valuation and Payment Structure - The acquisition involves a mix of cash and stock payments, with the issuance price set at 8.41 yuan per share, representing a discount compared to the current market price of 10.9 yuan [8][9]. - The valuation of Qianjin Xiangjiang's equity is estimated at 1.247 billion yuan, reflecting an increase of 87.77% from its book value, while Qianjin Xieli's equity is valued at 387 million yuan, up 73.28% [10].